Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 5/20 | 0.53 |
| ▸ | TLR4 | O00206 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798354 | 1.00 | RXRA (0.58) | RXRAFBP1TLR4TLR2PRMT1 | |
| SCHEMBL7313258 | 0.85 | RXRA (0.51) | RXRAFBP1TLR4TLR2PRMT1 | |
| SCHEMBL28594822 | 0.85 | RXRA (0.54) | RXRAFBP1TLR4TLR2PRMT1 | |
| SCHEMBL5733864 | 0.78 | HSP90AA1 (0.60) | RXRAFBP1PRMT1ALDH1A1MAPT | |
| SCHEMBL5733870 | 0.78 | HSP90AA1 (0.60) | RXRAFBP1PRMT1ALDH1A1MAPT | |
| SCHEMBL13930333 | 0.78 | RXRA (0.59) | RXRAFBP1TLR4TLR2PRMT1 | |
| SCHEMBL11077530 | 0.77 | FBP1 (0.56) | RXRAFBP1PRMT1ALDH1A1MAPT | |
| SCHEMBL11077527 | 0.77 | FBP1 (0.56) | RXRAFBP1PRMT1ALDH1A1MAPT | |
| SCHEMBL9357447 | 0.76 | RXRA (0.58) | RXRAFBP1TLR4TLR2PRMT1 | |
| SCHEMBL470811 | 0.76 | NFE2L2 (0.58) | RXRAFBP1TLR4TLR2PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4319015-A | USED AS SEPARATORS IN ION EXCHANGE RESIN FILTERS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-09 | — | — | US | claimed |
| CN-111217707-B | Preparation method of beta-trans-nitroolefin | 西北师范大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-113509959-A | Preparation method of hollow mesoporous nano silicon spheres for packaging chiral catalyst, product and application thereof | 重庆邮电大学 | 2021-10-19 | — | — | CN | disclosed |
| US-10908162-B2 | Methods related to volatile compounds in genitourinary cancers | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-02-02 | — | — | US | disclosed |
| CN-111217707-A | preparation method of β -trans-nitroolefin | 西北师范大学 | 2020-06-02 | — | — | CN | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190128890-A1 | METHODS RELATED TO VOLATILE COMPOUNDS IN GENITOURINARY CANCERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2770987-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9884048-B2 | ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-6329369-B1 | ANALGESICS FOR TREATING GLAUCOMA OR ELEVATED PRESSURE AND OTHER DISEASES WITH REDUCED SIDE EFFECTS BY TREATING A MAMMAL IN NEED THEREOF AN AGONIST OF ALPHA 2B OR ALPHA 2B/2C ADRENERGIC RECEPTOR | ALLERGAN SALES, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-1104407-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2001-06-06 | — | — | EP | disclosed |
| CN-1284066-A | Substituted imidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors | ALLERGEN SALES INC (US) | 2001-02-14 | — | — | CN | disclosed |
| WO-2001000586-A1 | COMPOUNDS AS SELECTIVE AGONISTS AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-1036065-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | Allergan Sales, Inc. (US) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999028300-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES HAVING AGONIST-LIKE ACTIVITY AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS | ALLERGAN SALES, INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| EP-0010265-B1 | SYNTHETIC RESINS BASED ON CROSSLINKED COPOLYMERS OF MONO- AND POLYVINYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS INERT MATERIAL IN ION EXCHANGE MIXED-BED FILTERS | BAYER AG (DE) | 1982-04-14 | — | — | EP | disclosed |
| US-4319015-A | USED AS SEPARATORS IN ION EXCHANGE RESIN FILTERS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-03-09 | — | — | US | disclosed |
| EP-0010265-A2 | Synthetic resins based on crosslinked copolymers of mono- and polyvinyl compounds, process for their preparation and their use as inert material in ion exchange mixed-bed filters | BAYER AG (DE) | 1980-04-30 | — | — | EP | disclosed |
| US-3931220-A | FUNGICIDE, BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | RXRA 4236/4885FBP1 364/4885TLR4 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.